Notably, TROP2-ADCs reprogram the tumor microenvironment by inhibiting macrophage and fibroblast recruitment, offering a potential strategy to overcome hepatic immune tolerance in combinatorial therapies (25). This evidence concerns the gene TACSTD2 and neoplasm.